[HTML][HTML] Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report

Y Noda, T Miyoshi, H Oe, Y Ohno, K Nakamura… - Cardiovascular …, 2013 - Springer
Y Noda, T Miyoshi, H Oe, Y Ohno, K Nakamura, N Toh, K Kohno, H Morita, K Kusano, H Ito
Cardiovascular diabetology, 2013Springer
Background Postprandial hyperlipidemia impairs endothelial function and participates in the
development of atherosclerosis. We investigated the postprandial effects of a dipeptidyl
peptidase IV inhibitor, alogliptin, on endothelial dysfunction and the lipid profile. Methods A
randomized cross-over trial design in 10 healthy volunteers (8 males and 2 females, 35±10
years) was performed. The postprandial effects before and after a 1-week treatment of 25
mg/day alogliptin on endothelial function were assessed with brachial artery flow-mediated …
Background
Postprandial hyperlipidemia impairs endothelial function and participates in the development of atherosclerosis. We investigated the postprandial effects of a dipeptidyl peptidase IV inhibitor, alogliptin, on endothelial dysfunction and the lipid profile.
Methods
A randomized cross-over trial design in 10 healthy volunteers (8 males and 2 females, 35 ± 10 years) was performed. The postprandial effects before and after a 1-week treatment of 25 mg/day alogliptin on endothelial function were assessed with brachial artery flow-mediated dilation (FMD) and changing levels of lipids, apolipoprotein B48 (apoB-48), glucose, glucagon, insulin, and glucagon-like peptide-1 (GLP-1) during fasting and at 2, 4, 6, and 8 h after a standard meal loading test.
Results
Alogliptin treatment significantly suppressed the postprandial elevation in serum triglyceride (incremental area under the curve [AUC]; 279 ± 31 vs. 182 ± 32 mg h/dl, p = 0.01), apoB-48 (incremental AUC; 15.4 ± 1.7 vs. 11.7 ± 1.1 μg h/ml, p = 0.04), and remnant lipoprotein cholesterol (RLP-C) (incremental AUC: 29.3 ± 3.2 vs. 17.6 ± 3.3 mg h/dl, p = 0.01). GLP-1 secretion was significantly increased after alogliptin treatment. Postprandial endothelial dysfunction (maximum decrease in%FMD, from −4.2 ± 0.5% to −2.6 ± 0.4%, p = 0.03) was significantly associated with the maximum change in apoB-48 (r = −0.46, p = 0.03) and RLP-C (r = −0.45, p = 0.04).
Conclusion
Alogliptin significantly improved postprandial endothelial dysfunction and postprandial lipemia, suggesting that alogliptin may be a promising anti-atherogenic agent.
Springer